Three Relatively Unknown Companies Entering US Market

Two Canadian companies and one from Israel are on the verge of entering the large and lucrative US market, hoping to cash in.


Pembina

Pembina Pipeline is a NYSE listed company (PBA), is an energy infrastructure company relatively unknown to most US investors. The coming months will change their profile in the US, as they are aiming to make a positive final investment decision to purchase Jordan Cove liquid natural gas (LNG) export facility along the coast of Oregon, for $10 billion.
Pembina received conditional approval from the Federal Energy Regulatory Commission (FERC) if it adheres to strict rules about reducing its environmental impact.


Canada Goose
Canada Goose manufactures high-end winter clothing, and is already a popular brand in the US, but its direct retail presence in the lower 50 is minuscule. With only 4 stores in the US (and only 11 worldwide) the company is poised to make an impact on the US retail market.
The company is planning on opening its 5th store in the US at the Mall of America in Bloomington, Minnesota, the location picked because it is a key tourist destination. The store will even feature a “cold room” where customers can try the coats on in the environment they were meant to be worn in.


UroGen Pharma
Israeli-based UroGen Pharma (NASDAQ-URGN) plummeted 34% over the past 12 months, and 10% since the beginning of 2019, but investors should think of the price decline as a bargain and opportunity, and not necessarily a warning.
The company develops drugs to treat rare cancers of the urinary tract. UGN-101 is the company’s leading candidate for approval in the US, as it has built a good reputation leading up to approval by US regulators later in 2019.
Analysts say the drug should reach peak yearly sales of over $500 million. This might not seem like much compared to top selling pharmaceuticals that can make as much as $1 billion, but the company today is valued at only $800 million. Bottom line, most investors are in the dark about UroGen Pharma, but we expect that to change before 2019 ends.

James Cannon

About James Cannon

James Cannon is an experienced hedge fund analyst. He has served on the advisory boards for various different Fortune 500 companies as well as serving as an adjunct professor of finance. James Cannon has written for a variety of Financial Magazines both on and off line. Contact James at james[at]businessdistrict.com